Boehringer Ingelheim reports first-half 2026 sales growth, driven by JARDIANCE® and new product launches in the U.S.
• Boehringer Ingelheim reported first-half 2026 net sales of EUR 15.8 billion for its Human Pharma division, fueled by strong U.S. demand and the performance of JARDIANCE®. • The company expanded its R&D pipeline to approximately 80 projects, advancing key assets including the cancer immunotherapy obrixtamig and the kidney disease drug apecotrep. • Research momentum remains high with five new compounds entering clinical trials, while the Animal Health sector focuses on new product launches and responding to disease outbreaks.
globenewswire.com


